"Major Advance" Declared in Metastatic Melanoma -- And It's Only Phase 1

Monday 6 September 2010

It is a "major advance in the treatment of metastatic melanoma." That's how 2 melanoma experts describe newly published data on the investigational agent PLX4032 (Plexxikon/Roche) — even though the data come from a phase 1 trial.

>> http://www.medscape.com/viewarticle/727427?sssdmh=dm1.634149&src=nldne&uac=152441AJ


Further information

European Oncology Nursing Society
Avenue E. Mounier 83
B-1200 Brussels
Belgium
Tel: +32 (0)2 779 9923
Fax: +32 (0)2 779 9937
eons.secretariat@cancernurse.eu